Pfizer’s GSK consumer deal is closed, and generics go next. Will its cash flow recover?
The mammoth consumer health deal Pfizer and GlaxoSmithKline struck last December is finally sealed. But things are looking markedly different at Pfizer than they did seven months ago—and that may not be a good thing, analysts say. Earlier this week, the New York drugmaker agreed to merge its off-patent drugs business, dubbed Upjohn, with Mylan,… Read More »